Aripiprazole
- Generic Name
- Aripiprazole
- Brand Names
- Abilify, Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen), Abilify Maintena, Aripiprazole Accord, Aripiprazole Sandoz, Aripiprazole Zentiva
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27Cl2N3O2
- CAS Number
- 129722-12-9
- Unique Ingredient Identifier
- 82VFR53I78
- Background
Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A ...
- Indication
Aripiprazole is indicated for the treatment of acute manic and mixed episodes associated with bipolar I disorder, irritability associated with autism spectrum disorder, schizophrenia, and Tourette's disorder. It is also used as an adjunctive treatment of major depressive disorder.[L45859 An injectable formulation of aripiprazole is indicated for agitation as...
- Associated Conditions
- Agitation, Bipolar 1 Disorder, Irritability, Major Depressive Disorder (MDD), Mixed manic depressive episode, Psychosis, Psychotic Depression, Schizophrenia, Tourette's Disorder (TD), Acute Manic episode
- Associated Therapies
- Monotherapy
Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and Quetiapine
- Conditions
- Interventions
- First Posted Date
- 2006-04-10
- Last Posted Date
- 2014-01-13
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 30
- Registration Number
- NCT00312598
An Open-Label Trial of Aripiprazole in Autism Spectrum Disorders
- Conditions
- Interventions
- First Posted Date
- 2006-03-29
- Last Posted Date
- 2017-02-15
- Lead Sponsor
- Cambridge Health Alliance
- Target Recruit Count
- 14
- Registration Number
- NCT00308074
- Locations
- 🇺🇸
Cambridge Health Alliance, Medford, Massachusetts, United States
Aripiprazole Associated With Methylphenidate in Children and Adolescents With Bipolar Disorder and ADHD
- Conditions
- First Posted Date
- 2006-03-21
- Last Posted Date
- 2008-08-07
- Lead Sponsor
- Federal University of Rio Grande do Sul
- Target Recruit Count
- 20
- Registration Number
- NCT00305370
- Locations
- 🇧🇷
ADHD Outpatient Program, Porto Alegre, RS, Brazil
Acute Psychosis Treatment in the Long Term, Unitary Group Study (APLUS)
- Conditions
- First Posted Date
- 2006-03-20
- Last Posted Date
- 2009-12-17
- Lead Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT00304655
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
A Study of Adjunctive Treatment of Aripiprazole in Schizophrenic Patients
- First Posted Date
- 2006-03-10
- Last Posted Date
- 2013-11-08
- Target Recruit Count
- 200
- Registration Number
- NCT00300846
- Locations
- 🇬🇧
Local Institution, London, United Kingdom
A Study of Aripiprazole in Patients With Schizophrenia in General Psychiatric Practices
- Conditions
- First Posted Date
- 2006-02-16
- Last Posted Date
- 2013-11-08
- Target Recruit Count
- 400
- Registration Number
- NCT00292409
Aripiprazole in the Treatment of Acutely Relapsed Patients With Schizophrenia
- Conditions
- First Posted Date
- 2006-01-27
- Last Posted Date
- 2008-05-15
- Lead Sponsor
- Taiwan Otsuka Pharm. Co., Ltd
- Target Recruit Count
- 83
- Registration Number
- NCT00283179
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
Aripiprazole in the Treatment of Tourette's Syndrome
- Conditions
- First Posted Date
- 2006-01-25
- Last Posted Date
- 2011-10-05
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 40
- Registration Number
- NCT00282139
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
Treatment of Children With ADHD Who do Not Fully Respond to Stimulants
- Conditions
- Interventions
- First Posted Date
- 2006-01-19
- Last Posted Date
- 2020-06-19
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 10
- Registration Number
- NCT00279409
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
Aripiprazole Augmentation Therapy in Treatment-resistant Depression
- First Posted Date
- 2006-01-13
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- University Hospital Freiburg
- Registration Number
- NCT00276978
- Locations
- 🇩🇪
Dept. of Psychiatry, University of Freiburg, Freiburg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.